Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Cell Biology International|May 25, 2010
Addressing the design of in vitro models for the investigation of microcystins: the essential role of transporter-mediated uptakeNoel R Monks, Jeffrey A Moscow
Journal of Cellular Biochemistry|January 13, 2006
Targeting the NF-kappa B pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAsNoel R Monks, Arthur B Pardee
Toxicon : Official Journal of the International Society on Toxinology|December 1, 2009
Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibitionAbigail Daily, Noel R Monks, Markos Leggas, et al.
Molecular Cancer Therapeutics|February 20, 2007
Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cellsNoel R Monks, Shuqian Liu, Yongsheng Xu, et al.
Cancer Chemotherapy and Pharmacology|October 16, 2009
Sensitivity of breast cancer cell lines to recombinant thiaminase IShuqian Liu, Noel R Monks, Jeremiah W Hanes, et al.
Pediatric Blood & Cancer|April 28, 2017
Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemiaIchiko Kinjyo, Ksenia Matlawska-Wasowska, Xiaoru Chen, et al.
Journal of Translational Medicine|September 18, 2013
Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumorsJacqueline D Peacock, David Cherba, Kevin Kampfschulte, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 6, 2017
Oncolytic VSV Primes Differential Responses to Immuno-oncology TherapyNicholas M Durham, Kathy Mulgrew, Kelly McGlinchey, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 3, 2013
Melanoma genotypes and phenotypes get personalJose M Pimiento, Eileen M Larkin, Keiran Sm Smalley, et al.
European Journal of Cancer (Oxford, England : 1990)|July 12, 2002
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767Noel R Monks, David C Blakey, Simon J East, et al.
Pageof 2